The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback